Sign in →

Test ID CERAM MI-Heart Ceramides, Plasma

Useful For

Evaluating for the risk of major adverse cardiovascular events within the next 1 to 5 years


Plasma ceramides predict risk of myocardial infarction, coronary revascularization, acute coronary syndrome hospitalization and mortality within 5 years.


Risk conferred by plasma ceramides is independent of low-density lipoprotein (LDL) cholesterol, C-reactive protein, LDL particles, and lipoprotein-associated phospholipase A2.


Plasma ceramides can be lowered by diet, exercise, simvastatin, rosuvastatin, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.

Method Name

Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)

Reporting Name

MI-Heart Ceramides, P

Specimen Type

Plasma EDTA

Specimen Required

Patient Preparation: Patients should not be receiving Intralipid because it may cause false-elevations in measured ceramides

Collection Container/Tube: Lavender top (EDTA)

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions: Centrifuge, aliquot at least 1 mL of plasma into a plastic vial, and freeze within 8 hours.

Specimen Minimum Volume

0.5 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Plasma EDTA Frozen (preferred) 30 days
  Refrigerated  24 hours
  Ambient  8 hours

Reference Values

MI-Heart Ceramide Risk Score:

0-2 Lower risk

3-6 Moderate risk

7-9 Increased risk

10-12 Higher risk

Ceramide (16:0): 0.19-0.36 mcmol/L

Ceramide (18:0): 0.05-0.14 mcmol/L

Ceramide (24:1): 0.65-1.65 mcmol/L

Ceramide (16:0)/(24:0): <0.11

Ceramide (18:0)/(24:0): <0.05

Ceramide (24:1)/(24:0): <0.45


Reference values have not been established for patients who are <18 years of age.


Note: Ceramide (24:0) alone has not been independently associated with disease and will not be reported.

Day(s) and Time(s) Performed

Tuesday, Friday; 7 a.m.

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information


LOINC Code Information

Test ID Test Order Name Order LOINC Value
CERAM MI-Heart Ceramides, P 93883-7


Result ID Test Result Name Result LOINC Value
42434 MI-Heart Ceramide Risk Score 93876-1
42428 Ceramide (16:0) 93882-9
42429 Ceramide (18:0) 93881-1
42430 Ceramide (24:1) 93880-3
42431 Ceramide (16:0)/(24:0) ratio 93879-5
42432 Ceramide (18:0)/(24:0) ratio 93878-7
42433 Ceramide (24:1)/(24:0) ratio 93877-9

NY State Approved



If not ordering electronically, complete, print, and send a Cardiovascular Test Request Form (T724) with the specimen.